CSIMarket Company Name, Ticker, Customers, else..
 
Zevra Therapeutics Inc   (NASDAQ: ZVRA)
Other Ticker:  
 
 
Price: $8.9100 $0.25 2.887%
Day's High: $8.915 Week Perf: 13.21 %
Day's Low: $ 8.51 30 Day Perf: 30.65 %
Volume (M): 552 52 Wk High: $ 9.76
Volume (M$): $ 4,922 52 Wk Avg: $7.34
Open: $8.57 52 Wk Low: $4.20



 Market Capitalization (Millions $) 482
 Shares Outstanding (Millions) 54
 Employees 23
 Revenues (TTM) (Millions $) 41
 Net Income (TTM) (Millions $) -92
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 6

Zevra Therapeutics Inc
Zevra Therapeutics Inc is a pharmaceutical company that focuses on developing innovative and effective treatment options for various medical conditions. They are dedicated to advancing medical science through research and development of novel therapeutics. The company aims to address unmet medical needs and improve the lives of patients by bringing forward safe and reliable therapies. Zevra Therapeutics Inc aims to collaborate with healthcare professionals, patients, and partners to bring their products to market and make a positive impact in the healthcare industry.


   Company Address: 1180 Celebration Boulevard, Suite 103 Celebration 34747 FL
   Company Phone Number: 939-3416   Stock Exchange / Ticker: NASDAQ ZVRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        27.85% 
ALKS        1.98% 
BMRN   -0.62%    
HRMY        4.48% 
JAZZ        6.68% 
SUPN        2.4% 
• View Complete Report
   



Product Service News

Zevra Therapeutics Launches Pioneering Campaign for Niemann-Pick Disease Type C Awareness Amid Financial Challenges

Published Fri, Feb 28 2025 12:59 PM UTC

In the ever-evolving landscape of biotechnology and pharmaceuticals, the proactive approach to disease awareness and early diagnosis has never been more critical. Zevra Therapeutics Inc. a company dedicated to pioneering treatments for rare diseases, is stepping up its commitment with the launch of the Learn NPC, Read Between the Signs campaign. This new initiative aims to e...
Merger and Acquisition

Zevra Therapeutics? Bold Move: Cashing in $150 Million from Rare Disease Voucher Sale!,

Published Thu, Feb 27 2025 12:31 PM UTC

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million: Strategic Moves in a Dynamic MarketCelebration, Fla. Feb. 27, 2025 ? Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a prominent player in the pharmaceutical industry dedicated to developing therapies for individuals with rare diseases, has made waves in the market wi...
Management Announcement

Zevra Therapeutics Announces Organizational Changes

Published Fri, Dec 6 2024 10:00 PM UTC

Article for the CSI MarketZevra Therapeutics: Transformational Challenges Amidst Financial Strain in Rare Disease TherapeuticsCELEBRATION, Fla. ? In a striving industry defined by rapid innovation and harsh competition, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) finds itself at a critical juncture. The company, dedicated to addressing the unmet therapeutic needs of patients a...
Clinical Study

Breakthrough in Niemann-Pick Disease Type C Treatment of MIPLYFFA (arimoclomol) into the U.S. Market

Published Thu, Nov 21 2024 9:52 PM UTC

: Niemann-Pick Disease Type C (NPC) is a rare, progressive genetic disorder characterized by the malfunction of lipid transport within cells, leading to a variety of debilitating symptoms and poor quality of life. Until recently, there has been a significant unmet medical need for effective therapeutic interventions for NPC. The approval and subsequent commercial availabilit...
Clinical Study

Zevra Therapeutics Reveals Promising Phase 2 Trial Results for KP1077 in Idiopathic Hypersomnia Ahead of Sleep Europe...

Published Tue, Sep 24 2024 11:30 AM UTC

In the ever-evolving landscape of clinical research and drug development, the spotlight is increasingly shining on therapies addressing rare sleep disorders. As the upcoming Sleep Europe 2024 conference approaches, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is poised to make significant waves in this domain. The company plans to present top-line data from its Phase 2 clinical tr...






Zevra Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com